Optimizing the Cell Painting assay for image-based profiling.


Journal

Nature protocols
ISSN: 1750-2799
Titre abrégé: Nat Protoc
Pays: England
ID NLM: 101284307

Informations de publication

Date de publication:
07 2023
Historique:
received: 13 07 2022
accepted: 28 03 2023
pmc-release: 01 07 2024
medline: 12 7 2023
pubmed: 22 6 2023
entrez: 21 6 2023
Statut: ppublish

Résumé

In image-based profiling, software extracts thousands of morphological features of cells from multi-channel fluorescence microscopy images, yielding single-cell profiles that can be used for basic research and drug discovery. Powerful applications have been proven, including clustering chemical and genetic perturbations on the basis of their similar morphological impact, identifying disease phenotypes by observing differences in profiles between healthy and diseased cells and predicting assay outcomes by using machine learning, among many others. Here, we provide an updated protocol for the most popular assay for image-based profiling, Cell Painting. Introduced in 2013, it uses six stains imaged in five channels and labels eight diverse components of the cell: DNA, cytoplasmic RNA, nucleoli, actin, Golgi apparatus, plasma membrane, endoplasmic reticulum and mitochondria. The original protocol was updated in 2016 on the basis of several years' experience running it at two sites, after optimizing it by visual stain quality. Here, we describe the work of the Joint Undertaking for Morphological Profiling Cell Painting Consortium, to improve upon the assay via quantitative optimization by measuring the assay's ability to detect morphological phenotypes and group similar perturbations together. The assay gives very robust outputs despite various changes to the protocol, and two vendors' dyes work equivalently well. We present Cell Painting version 3, in which some steps are simplified and several stain concentrations can be reduced, saving costs. Cell culture and image acquisition take 1-2 weeks for typically sized batches of ≤20 plates; feature extraction and data analysis take an additional 1-2 weeks.This protocol is an update to Nat. Protoc. 11, 1757-1774 (2016): https://doi.org/10.1038/nprot.2016.105.

Identifiants

pubmed: 37344608
doi: 10.1038/s41596-023-00840-9
pii: 10.1038/s41596-023-00840-9
pmc: PMC10536784
mid: NIHMS1924054
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1981-2013

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM122547
Pays : United States

Informations de copyright

© 2023. Springer Nature Limited.

Références

Nat Protoc. 2016 Sep;11(9):1757-74
pubmed: 27560178
Nat Methods. 2022 Dec;19(12):1550-1557
pubmed: 36344834
Nat Commun. 2023 Apr 8;14(1):1967
pubmed: 37031208
Curr Protoc. 2021 May;1(5):e89
pubmed: 34038030
Nat Rev Drug Discov. 2021 Feb;20(2):145-159
pubmed: 33353986
Cytometry A. 2023 Oct 3;:
pubmed: 37789738
Mol Reprod Dev. 2015 Jul-Aug;82(7-8):518-29
pubmed: 26153368
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Elife. 2017 Mar 18;6:
pubmed: 28315521
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):10911-6
pubmed: 25024206
Sci Rep. 2022 Jun 15;12(1):10001
pubmed: 35705591
Cell Rep. 2020 Nov 10;33(6):108371
pubmed: 33176151
Cell Chem Biol. 2018 May 17;25(5):611-618.e3
pubmed: 29503208
Nat Methods. 2017 Aug 31;14(9):849-863
pubmed: 28858338
Methods Mol Biol. 2013;986:105-22
pubmed: 23436409
Toxicol Appl Pharmacol. 2020 Jan 15;389:114876
pubmed: 31899216
J Biomol Screen. 2009 Jun;14(5):444-51
pubmed: 19483148
Nat Methods. 2019 Dec;16(12):1247-1253
pubmed: 31636459
Mol Biol Cell. 2022 May 15;33(6):ar49
pubmed: 35353015
PLoS One. 2013 Dec 02;8(12):e80999
pubmed: 24312513
PeerJ. 2014 Jun 19;2:e453
pubmed: 25024921
Cell Syst. 2022 Sep 21;13(9):724-736.e9
pubmed: 36057257
Cell Syst. 2022 Nov 16;13(11):911-923.e9
pubmed: 36395727
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
J Microsc. 2014 Dec;256(3):231-6
pubmed: 25228240
Nat Methods. 2021 Jan;18(1):100-106
pubmed: 33318659
Nat Commun. 2021 Mar 25;12(1):1883
pubmed: 33767198
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cell Genom. 2023 Jun 20;3(7):100346
pubmed: 37492099
J Biomol Screen. 2003 Oct;8(5):566-70
pubmed: 14567784
Curr Protoc. 2023 Mar;3(3):e713
pubmed: 36921124
Curr Opin Chem Biol. 2021 Dec;65:9-17
pubmed: 34023800

Auteurs

Beth A Cimini (BA)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Srinivas Niranj Chandrasekaran (SN)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Maria Kost-Alimova (M)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Lisa Miller (L)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Amy Goodale (A)

Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Briana Fritchman (B)

Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Patrick Byrne (P)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Sakshi Garg (S)

Merck Healthcare KGaA, Darmstadt, Germany.

Nasim Jamali (N)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

David J Logan (DJ)

Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.

John B Concannon (JB)

Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

Charles-Hugues Lardeau (CH)

Janssen Pharmaceutica N.V., Beerse, Belgium.

Elizabeth Mouchet (E)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

Shantanu Singh (S)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Hamdah Shafqat Abbasi (H)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Peter Aspesi (P)

Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

Justin D Boyd (JD)

Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.

Tamara Gilbert (T)

Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.

David Gnutt (D)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Santosh Hariharan (S)

Discovery Sciences, Pfizer, Groton, CT, USA.

Desiree Hernandez (D)

Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Gisela Hormel (G)

Merck Healthcare KGaA, Darmstadt, Germany.

Karolina Juhani (K)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

Michelle Melanson (M)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Lewis H Mervin (LH)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

Tiziana Monteverde (T)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

James E Pilling (JE)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

Adam Skepner (A)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Susanne E Swalley (SE)

Biogen, Inc., Cambridge, MA, USA.

Anita Vrcic (A)

Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Erin Weisbart (E)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Guy Williams (G)

AstraZeneca BioPharmaceuticals R&D, Cambridge, UK.

Shan Yu (S)

Takeda Development Center Americas, Inc., San Diego, CA, USA.

Bolek Zapiec (B)

Merck Healthcare KGaA, Darmstadt, Germany.

Anne E Carpenter (AE)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. anne@broadinstitute.org.

Articles similaires

Selecting optimal software code descriptors-The case of Java.

Yegor Bugayenko, Zamira Kholmatova, Artem Kruglov et al.
1.00
Software Algorithms Programming Languages

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Exploring blood-brain barrier passage using atomic weighted vector and machine learning.

Yoan Martínez-López, Paulina Phoobane, Yanaima Jauriga et al.
1.00
Blood-Brain Barrier Machine Learning Humans Support Vector Machine Software
1.00
Humans Magnetic Resonance Imaging Brain Infant, Newborn Infant, Premature

Classifications MeSH